Natera Inc. has announced the launch of the EDEN study, a large, multi-center prospective clinical trial designed to evaluate the company's non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications. The EDEN study aims to enroll up to 7,500 pregnant participants in the United States between 9 and 15 weeks' gestation. The trial will assess the performance of Natera's integrated prenatal risk assessment test, which combines cell-free DNA (cfDNA), additional analytes, and clinical data. The goal is to identify pregnancies at increased risk for preeclampsia—including earlier-onset and more severe disease—as well as other adverse pregnancy outcomes. Results from the EDEN study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260206350770) on February 06, 2026, and is solely responsible for the information contained therein.